background: Women with polycystic ovary syndrome (PCOS) frequently exhibit central obesity, glucose intolerance, atherogenic dyslipidemia and hypertension, which are characteristic features of a condition of cardiometabolic risk. Our objective was to investigate the relationship between visceral adiposity index (VAI) and phenotypic characteristics in women with PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is a hyperandrogenic and ovulatory disordered syndrome and is the most common endocrinopathy in women of reproductive age (Diamanti-Kandarakis et al., 1999) . Although there are undoubtedly subtypes of PCOS (as a syndrome with extreme phenotypic variety), insulin resistance and hyperinsulinemia are thought to be implicated in the pathogenesis of the syndrome in the majority of cases (Galluzzo et al., 2008) . Moreover, PCOS is associated with many features of the metabolic syndrome (MetS) (Conway et al., 1992) , a cluster of factors that have been shown to predict a greater risk of future cardiovascular events and type 2 diabetes (Reaven, 2002) . Although there is a paucity of data providing evidence for cardiovascular events in women affected by PCOS during their fertile years (Carmina, 2009) , an increased prevalence of cardiovascular risk factors has been well documented (Hoffman and Ehrmann, 2008) . It has been observed that obesity (especially abdominal obesity) and PCOS interact to promote premature atherosclerosis and increase cardiovascular mortality (Guzick et al., 1996; Birdsall et al., 1997; Pierpoint et al., 1998; Wild et al., 2000; Christian et al., 2003; Shaw et al., 2008) . For these reasons, in a recent Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society, BMI, waist circumference (WC), serum lipid/glucose and blood pressure determinations are recommended for all women with PCOS, as well as the oral glucose tolerance test (OGTT) in those with obesity, advanced age, personal history of gestational diabetes or family history of type 2 diabetes mellitus (Wild et al., 2010) . In addition, lifestyle management is recommended for primary cardiovascular disease prevention, targeting low-density lipoprotein (LDL) and non-high-density lipoprotein (HDL) cholesterol and adding insulin-sensitizing and other drugs if dyslipidemia or other risk factors persist (Wild et al., 2010) . These findings emphasize the importance of assessing 'cardiometabolic risk' in women with PCOS in clinical practice. Recently, our research group has proposed the visceral adiposity index (VAI), a mathematical model that uses simple anthropometric (BMI and WC), functional [triglycerides (TG) and HDL cholesterol] parameters . This simple surrogate marker of visceral adipose dysfunction (VAD) showed a strong association with both the rate of peripheral glucose utilization (M value) during euglycemic -hyperinsulinemic clamp and visceral adipose tissue (VAT) measured with magnetic resonance imaging (MRI). Furthermore, it showed a strong independent association with both cardiovascular and cerebrovascular events . Moreover, in a specific cohort of patients with genotype 1 chronic hepatitis C, VAD identified by a higher VAI score proved to be independently associated with both steatosis and necroinflammatory activity and directly correlated with viral load (Petta et al., 2010) .
The objective of this study was to evaluate the role of VAD (indirectly expressed by VAI) and of insulin sensitivity in PCOS and in its various phenotypic aspects. The following subjects were excluded from the study: amenorrheal women (absence of vaginal bleeding .6 months) as there were very few of these (14/275 cases), and those with various progesterone bleeding induction schemes, potentially interfering with sex hormone patterns; women treated with clomiphene citrate, oral contraceptives, antiandrogens, drugs to control their appetite or insulin-sensitizing drugs (metformin, pioglitazone and rosiglitazone) during the 6 months prior to the first examination; women with hyperprolactinemia; patients with 17OH-progesterone levels .6.05 nmol/l who, after 250 mg Synacthen (synthetic analogue of adrenocorticotrophic hormone), showed 17OH-progesterone .30.26 nmol/l at 60 min; women with dehydroepiandrosterone sulphate (DHEA-S) .16.32 mmol/l, who, when screened with a computerized axial tomography scan, presented adrenal hyperplasia or adenoma or virilizing androgen-secreting neoplasias; women whose clinical and hormone evaluation (phenotype, increased 24 h free urinary cortisol, high cortisol levels after 1 mg of overnight dexamethasone) suggested Cushing's syndrome; women with hypo-or hyperthyroidism.
Materials and Methods

Subjects
In addition, a control group of 144 eumenorrhoic/non-hirsute women (matched for age and BMI), with no family history of PCOS, was prospectively recruited from a consecutive series of 172 women of reproductive age followed up in our Outpatients Clinic (2008 Clinic ( -2010 for overweight/ obesity or normal weight with family history for diabetes, who had performed a diagnostic OGTT (75 g glucose) and had been tested for total testosterone, DHEA-S, D4androstenedione and sex hormone-binding globulin (SHBG). The 28 eumenorrhoic/non-hirsute excluded women were subjects who had some PCOS-related disturbances [hyperandrogenemia, previous ultrasonographic finding of polycystic ovary morphology (PCOM), history of irregular menses and infertility] but who did not fulfill the Rotterdam diagnostic criteria; hence, they might be most at risk for PCOS and should be carefully considered (Bloom et al., 2006) .
The following relevant data were obtained from our database: possible family history of diabetes, oligo-amenorrhea, hirsutism, acne and age of menarche; weight, BMI, WC, blood pressure and Ferriman -Gallwey (FG) score. It is routine practice in our Outpatients Clinic to evaluate the degree of hirsutism with the use of the FG map scoring system, which divides the body up into 11 domains. Hirsutism was defined as FG score .8 (Ferriman and Gallwey, 1961 During the follow-up in our Outpatients Clinic, patients were generally tested for FSH, LH, 17-b-estradiol (E 2 ), 17OH-progesterone, basal prolactin, total testosterone, DHEA-S, D4androstenedione, SHBG, total cholesterol, HDL cholesterol, LDL cholesterol and TG during the follicular phase (Day 7 from the beginning of the last period). On the same day, we also performed an OGTT (75 g glucose) and measured glycemia and insulinemia at 0, 30, 60, 90 and 120 min. Serum progesterone level was determined between Days 20 and 24 of the menstrual cycle and chronic oligoanovulation was established if two consecutive cycles were anovulatory [progesterone level ,3 ng/ml (international system (SI): ,9.54 nmol/l)] (Azziz et al., 2009) . Biochemical hyperandrogenism was diagnosed when androgen levels were as follows: total testosterone .2.84 nmol/l, DHEA-S .12.14 mmol/l, D4androstenedione .10.72 nmol/l (calculated on the basis of the 95th percentile upper limits of basal serum androgen normality in the control group of 144 healthy Sicilian eumenorrheal women without hirsutism and family history of PCOS). Transvaginal ovarian ultrasound scanning was performed between Days 5 and 10 from the beginning of the last period using a 7.5-MHz vaginal probe transducer (General Electric LOGIQ 400MD, Milwaukee, WI, USA). Both ovaries were measured in the sagittal, transverse and coronal planes. Ovaries were classified as polycystic if 12 or more follicles measuring 2 -8 mm in diameter were present in each ovary, and/or there was an increase in ovarian volume (.10 ml) (Chistensen et al., 1997; The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004; Carmina et al., 2005a,b) .
Assays
All hormones were measured in our laboratory using commercial kits. These included enzyme-linked immunosorbent assay (DRG Diagnostics, DRG Instruments GmbH, Germany) for FSH (mUI/ml), LH (mUI/ml), E 2 (pg/ ml), 17OH-progesterone (ng/ml), progesterone (ng/ml), prolactin (ng/ ml), total testosterone (ng/ml), D4androstenedione (ng/ml; Arnika, Visceral adiposity index and polycystic ovary syndrome Milan, Italy), insulin (mUI/l; the intra-and inter-assay coefficients of variation were ≤4 and ≤3.6%, respectively) and C-peptide (ng/ml). Chemiluminescence assays were used for DHEA-S (mg/dl; Immulite, Diagnostic Products, Genoa, Italy) and serum SHBG (nmol/l; Immulite, Diagnostic Products). Blood glucose levels (mg/dl) were measured using an electrochemical system (Glucocard, Menarini Diagnostics, Italy). Total cholesterol, HDL and TG were measured in our laboratory using standard assays. LDL cholesterol levels were calculated with Friedewald's formula. The conversion factors for the International System (SI) were the following: glucose (mg/ dl versus mmol/l: 0.0555), insulin (mUI/l versus pmol/l: 6.945), C-peptide (ng/dl versus nmol/l: 0.33), total cholesterol (mg/dl versus mmol/l: 0.0259), total testosterone (ng/ml versus nmol/l: 3.467), free testosterone (pg/ml versus pmol/l: 3.47), DHEA-S (mg/dl versus mmol/l: 0.0272), androstenedione (ng/ml versus nmol/l: 3.492), E 2 (pg/ml versus pmol/l: 3.671), 17OH-progesterone (ng/ml versus nmol/l: 3.026), progesterone (ng/ml versus nmol/l: 3.180), prolactin (ng/ml versus mg/l: 1), FSH (mUI/ml versus IU/l: 1) and LH (mUI/ml versus IU/l: 1).
Free androgen index (FAI) was calculated as the ratio of total testosterone levels in nmol/l to SHBG levels in nmol/l × 100 (%) (Vermeulen et al, 1999) . Insulin sensitivity was estimated indirectly using basal insulin and glucose values to calculate the homeostatic model of insulin resistance (HOMA-IR) (Matthews et al., 1985) [glycemia (mmol/l) × insulinemia (mU/ml)/22.5] and using glucose and insulin values during the OGTT to calculate the Matsuda index of insulin sensitivity (ISI Matsuda) (Matsuda and De Fronzo, 2001) [10 000/glucose (mg/dl) × insulin (mU/ml) × glucose mean × insulin mean]. The trapezoidal method was used for the calculation of AUC 2h-insulin and AUC 2h-glucose .
VAI score was calculated as described using the following sex-specific equations, where TG levels are expressed in mmol/l and HDL is expressed in mmol/l:
Statistical methods
The Statistical Package for the Social Sciences version 17 and MedCalc version 11.3 were used for data analysis. Baseline characteristics were presented as mean + SD for continuous variables; rates and proportions were calculated for categorical data. Normality of distribution for quantitative data was assessed by the Kolmogorov-Smirnov test. Because total cholesterol did not present normal distribution, it was logtransformed. Differences between two groups in univariate analysis were detected by the unpaired Student's t-test for continuous variables (after testing for equality of variance: Levene's test) and by the x 2 test and Fisher's exact test (when appropriate) for categorical variables.
A multiple logistic regression model was performed to explore the independence of the association between the different variables considered and PCOS. Variables associated with the dependent variable on univariate analysis (probability threshold, P ≤ 0.10) were included in two multivariate regression models. To avoid effects of multicollinearity with low HDL cholesterol (dichotomous variable), HDL and calculated LDL cholesterol (quantitative variables) were not included in either regression model. In the model, the following independent variables were included: total testosterone, FAI, DHEA-S, D4androstenedione, HOMA-IR, ISI Matsuda, AUC 2h-insulin , VAI score and total cholesterol as continuous variables; MetS (absent ¼ 0; present ¼ 1), high TG (absent ¼ 0; present ¼ 1) and low HDL cholesterol (absent ¼ 0; present ¼ 1) as categorical dichotomic variables.
The one-way analysis of variance was used for comparison between groups [oligomenorrhea + hyperandrogenism (O + H), oligomenorrhea + PCOM (O + P), hyperandrogenism + PCOM (H + P) and complete phenotypes (O + H + P) and control group)] after testing for equality of variance. The Fisher least significant difference (LSD) post hoc correction was applied if the variables had equal variances and the Dunnett post hoc correction if the variables did not have equal variances.
A P-value of ,0.05 was considered statistically significant.
Results
Among the 220 patients with PCOS retrospectively screened, 75% of women exhibited oligomenorrhea, 65% had low progesterone levels in the luteal phase (chronic oligo-anovulation), 75.9% had biochemical hyperandrogenemia (43.8% increased total testosterone, 17.8% increased DHEA-S and 66.5% increased D4androstenedione), 62.7% had hirsutism, 37.3% had acne/seborrhea and 80% ultrasonographic findings of PCOM. The demographic, clinical and biochemical characteristics (including anthropometric measurements, hormonal profile and metabolic profile) of the 220 PCOS-women and 144 control women are presented in Table I In univariate analysis, the PCOS group showed a significant increase in the prevalence of MetS compared with the control group (27.7 versus 16%; P ¼ 0.009), owing to the increased prevalence of high TG (28.6 versus 14.6%; P ¼ 0.002) and low HDL cholesterol (59.1 versus 38.2%; P , 0.001); no difference was found for the other components of MetS and for the glucose tolerance categories (Table I) . Furthermore, compared with the control group, PCOS women showed a significant increase in total testosterone (P ¼ 0.013), FAI (P , 0.001), DHEA-S (P ¼ 0.041), D4androstenedione (P ¼ 0.003), AUC 2h-insulin (P , 0.001) and VAI score (P ¼ 0.001), whereas a significant reduction was observed regarding ISI Matsuda (P ¼ 0.036; Table I ). For all of these variables, at multivariate analysis, only AUC 2h-insulin [odds ratio (OR): 1.00; 95% confidence interval (CI): 1.00 -1.00; P ¼ 0.003] and VAI score (OR: 1.81; 95% CI: 1.20 -2.73; P ¼ 0.005) showed an independent association with PCOS (Table I) .
The 220 women with PCOS were subsequently divided into four groups (four phenotypes resulting from application of the Rotterdam Criteria): 82 (37.27%) with complete phenotype (O + H + P), 43 (19.54%) with O + H phenotype, 43 (19.54%) with O + P phenotype and 52 (23.63) with H + P phenotype. Interestingly, a high prevalence (50%) of chronic oligo-anovulation in the non-ovulatory phenotype (H + P) was also observed, although lower than the complete phenotype (72%; P ¼ 0.017) but with no significant differences from the O + H (69.8%; P ¼ 0.081) and the O + P (65.1%; P ¼ 0.203) phenotypes (Table II) . We next examined the prevalence of MetS and of each of its components: O + H phenotype and complete phenotype showed a higher prevalence of MetS than the control group (37.2 versus 16%, P ¼ 0.005; 29.3 versus 16%, respectively; P ¼ 0.024), mainly related to a higher prevalence of high TG (39.5 and 31.7 versus 14.6%, respectively; P ¼ 0.001) and of low HDL cholesterol (60.5 and 64.6 versus 38.2%, respectively; P ¼ 0.002) (Table II) .
Hormonal profiles
The complete phenotype showed higher levels of FSH (P ¼ 0.013) and lower levels of E 2 (P ¼ 0.008), 17OH-progesterone (P ¼ 0.039) and progesterone (P , 0.001) compared with other phenotypes (Table III) Visceral adiposity index and polycystic ovary syndrome
Compared with the control group, all phenotypes showed higher levels of total testosterone, whereas a higher FAI was only observed in hyperandrogenic phenotypes (i.e. O + H, H + P and complete phenotype). Higher DHEA-S levels compared with the control group were found in the O + H and in the complete phenotype, whereas an increase in D4androstenedione was only observed in the complete phenotype (Table III) .
Metabolic profiles
Compared with the control group, only the O + H phenotype showed a higher HOMA-IR (P ¼ 0.037) and only the H + P phenotype showed a lower ISI Matsuda (P ¼ 0.007). All hyperandrogenic phenotypes showed a higher AUC 2h-insulin compared with the control group, whereas the pure ovulatory phenotype (O + P) showed no difference. In contrast, all the phenotypes with oligomenorrhea showed a higher VAI score than the control group (Table III) .
Regarding the lipid profile, the total cholesterol levels were higher in phenotype H + P than in the control women (P , 0.001) but were no different from those in the other three phenotypes. The HDL cholesterol levels were lower in O + H (P ¼ 0.005) and complete phenotypes (P , 0.001) than in control women. The TG levels were higher only in the complete phenotype (P ¼ 0.030) than in the control group (Table III) .
Systemic blood pressure profile
No significant differences were found between the groups in the prevalence of high blood pressure (Table II) . The women with high blood pressure had a higher VAI score than normotensive women in the O + H phenotype (4.00 + 0.72 versus 2.24 + 1.41; P ¼ 0.001), the O + P phenotype (4.61 + 1.34 versus 1.94 + 1.09; P ¼ 0.009) and complete phenotype (3.54 + 0.88 versus 2.35 + 1.13; P ¼ 0.011) but not in the H + P phenotype (1.86 + 0.55 versus 1.66 + 1.04; P ¼ 0.515) or the control group (1.77 + 1.19 versus 1.60 + 0.78; P ¼ 0.557).
Discussion
The present study aimed to characterize cardiometabolic risk in the four PCOS phenotypes as defined by the Rotterdam criteria and to compare this with control subjects.
In the past, PCOS was largely defined as a syndrome with a predominant hyperandrogenic profile, so much so that none of the three diagnostic criteria used to date [National Institutes of Health (Zawadski and Dunaif, 1992) , Rotterdam (The Rotterdam ESHRE/ ASRM-sponsored PCOS consensus workshop group, 2004) and AE-PCOS (Azziz et al., 2006) criteria] include an assessment of anthropometric (i.e. BMI and WC) and metabolic parameters. Recently, a confirmation of the major attention of the scientific community to the metabolic aspects of PCOS was demonstrated by the recent position expressed by the AE-PCOS Society (Wild et al. 2010) . In our study, comparing women with PCOS to controls who were matched for age and BMI, the only aspects that show an independent association with PCOS are visceral adipose function (indirectly expressed by VAI) and compensatory hyperinsulinism (expressed by AUC 2h-insulin ). We found no independent association between insulin sensitivity (indirectly expressed by HOMA-IR and ISI Matsuda), androgens and PCOS.
These data seem to conflict with a previous study where no regional differences in patterns of fat distribution between PCOS cases and control women were shown by MRI (Barber et al., 2008) , but in this study, which carried out detailed morphological assessments in women with PCOS and controls, the quantitative ratio between visceral and subcutaneous fat deposits was not examined, nor were indices of visceral adipose function (directly or indirectly) studied.
This association with visceral adipose function and with hyperinsulinism is explained in part by the occurrence of insulin resistance and compensatory hyperinsulinism in women with abdominal adiposity, overweight and obesity, and by the fact that systemic hyperinsulinism plays a major role in the development of the hyperandrogenism which is characteristic of PCOS (Dunaif, 1997) .
Hyperinsulinism might trigger the development of PCOS in predisposed women because insulin amplifies exaggerated androgen secretion, which is characteristic of these patients (Dunaif, 1997) . This condition is testified by the well-known high prevalence of PCOS in all those conditions characterized by hyperinsulinemia, such as obesity (Alvarez-Blasco et al., 2006) , gestational (Lo et al., 2006) and type 2 diabetes mellitus (Conn et al., 2000; Amini et al., 2008) , syndromes of extreme insulin resistance resulting from mutations in the insulin receptor gene (Musso et al., 2004) or from autoantibodies against the insulin receptor (Taylor et al., 1982) , or even insulinomas (Stanciu et al, 2003) . Furthermore, exogenous systemic hyperinsulinism in women with insulin-treated type 1 diabetes mellitus also frequently results in PCOS (Codner and Escobar-Morreale, 2007) . Moreover, in women with PCOS, the condition of VAD expressed by the high VAI might also contribute to ovarian and adrenal hyperandrogenism through mechanisms independent of insulin resistance; these mechanisms are detailed below and include low-grade chronic inflammation, secretion of adipokines, such as leptin, that exert direct effects on the ovary (Pasquali et al., 2006) and local metabolism of sex steroids and cortisol in visceral fat (Gambineri et al., 2002) .
In our study, the subdivision of participants into four Rotterdam phenotypes revealed a high prevalence of MetS in phenotypes with oligomenorrhea (O + H: 37.2%; O + P: 25.6%; complete phenotype: 29.3%) and showed a higher VAI score than in control women. These phenotypes also had a higher prevalence of chronic oligo-anovulation. Interestingly, we note that even the phenotype without oligomenorrhea (H + P) had 50% of cases with chronic oligo-anovulation: this datum underlines the importance of assessing the progesterone levels in the luteal phase in all women with PCOS.
Instead, a more marked hyperinsulinism than in the control group was present in phenotypes with hyperandrogenism (O + H, H + P and complete phenotype) and these women also had a higher FAI. These data are confirmed in other studies (Welt et al., 2006; Barber et al., 2007) in which hyperandrogenic phenotypes were associated with increased BMI and hyperinsulinism, suggesting that, aside from the well-established role of hyperinsulinism as a facilitating factor for androgen excess (Dunaif, 1997) , molecules secreted by adipose tissue might also influence ovarian function. Adipokines, such as leptin, and cytokines, such as tumor necrosis factor-a and interleukin-6, are not only involved in the pathogenesis of obesity-related insulin resistance (Mathieu et al., 2010) but also directly influence ovarian function (Escobar-Morreale and San Millàn, 2007).
However, these interesting aspects of VAT function in PCOS should be further investigated through studies comparing VAI score with adipocytokines in women with PCOS.
The most important point of our study that we wish to stress is the cardiometabolic risk in women with PCOS and high VAI score, particularly in those with O + H, O + P and complete phenotypes. What we found in the H + P phenotype (i.e. VAI comparable with that of control women) seems to be in contrast to some data concerning the evidence that the phenotypes with androgen excess have the highest cardiovascular risk (Carmina and Lobo, 2001; Lambrinoudaki, 2011) . In this regard, the data on metabolic complications in the ovulatory PCOS phenotype (H + P) are conflicting, since in this phenotype, other studies also showed that lipid levels, glucose and insulin concentrations were not different from those of control subjects (Norman et al., 1995; Carmina et al., 2005a,b) . However, these controversial data can be explained by the fact that PCOS is a syndrome that may vary during the life of women: the H + P phenotype can become a complete phenotype at other moments in life.
For these reasons, we suggest applying the VAI test to all women with PCOS, independent of the phenotype. Although VAI cannot be claimed per se as a diagnostic tool for cardiovascular and cerebrovascular events because it includes physical (BMI and WC) and metabolic (TG and HDL) parameters, it may, however, indirectly reflect other non-classical risk factors, i.e. altered production of adipocytokines, increased lipolytic activity and plasma-free fatty acids. Moreover, VAI showed a strong association with both the rate of peripheral glucose utilization (M value) during euglycemic -hyperinsulinemic clamp and with VAT measured with MRI . For these reasons, in the future, it is necessary to identify the precise cut-off reference value for identifying cardiometabolic risk in patients with PCOS; this could be useful for starting diagnosis early (complete lipid pattern, OGTT, electrocardiography, intimal -media thickening etc.) and therapeutic personalized programs for the patients identified as being at risk.
In conclusion, given the simplicity of WC and BMI measurement and TG and HDL assessment, we suggest that VAI could be an easy tool for the assessment of visceral adipose function in women with hyperandrogenism and/or oligo-amenorrhea and/or PCOM, and might be useful in daily clinical practice and in population studies for the assessment of cardiometabolic risk associated with PCOS.
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